Apellis Pharmaceuticals, Inc. (APLS) Tops Q2 EPS by 34c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($1.02), $0.34 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $95 million versus the consensus estimate of $70.24 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Akari Therapeutics adds oncology expert Patricia LoRusso to advisory board
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M